Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
Breast Cancer Res Treat. 2022 Jan;191(1):223-224.
doi: 10.1007/s10549-021-06374-6.
1 Division of Breast Medical Oncology, Department of Breast and Thoracic Oncology Director, Istituto Nazionale Tumori IRCCS "Fondazione Pascale", Napoli, Italy. m.delaurentiis@istitutotumori.na.it.
2 Institute of Oncology Ljubljana, Ljubljana, Slovenia.
3 Western Cancer Institute, Nantes, France.
4 Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
5 Virgen del Rocío University Hospital, Biomedicine Institute, Seville, Spain.
6 Montpellier Cancer Institute, Montpellier, France.
7 The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada.
8 Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.
9 Gregorio Marañón General University Hospital, GEICAM, Universidad Complutense, CIBERONC, Madrid, Spain.
10 Royal Marsden Hospital NHS Foundation Trust, Sutton, UK.
11 Curie Institute, Paris, France.
12 USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
13 University Hospital 12 de Octubre, Clara Campal Comprehensive Cancer Center (HM CIOCC), Madrid, Spain.
14 Faculty of Medicine, Cairo University, Cairo, Egypt.
15 Tata Medical Center, Kolkata, India.
16 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
17 Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italia.